Wednesday, 18 Oct 2017

You are here

Pregnancy Flares in RA and Spondylitis

Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission.  Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.

This issue has been further examined in a cohort of 136 pregnant patients with RA and axial spondyloarthritis (axSpA) who were prospectively followed before, during, and after pregnancy.

During pregnancy flares occurred in 29% of RA patients and in 25% of SpA patients.

In RA patients, 15/75 discontinued their tumor necrosis factor inhibitor (TNFi) at the time of a positive pregnancy test, with a nearly 3 fold increased the risk for flare (RR 3.33 (95% CI 1.8-6.1).

Flares were managed with either TNFi or glucocorticosteroid (GC) treatment and yielded improvement in 60%.

Of 61 patients with axSpA, 24 patients were on TNFi and discontinued the treatment at the time of the positive pregnancy test. In axSpA stopping TNFi, also increased the risk of flare (RR 3.08 (95% CI 1.2-7.9).

Patients with axSpA without TNFi in the preconception period showed persistent high disease activity from prepregnancy until the postpartum period.

These data speak to the need for ongoing TNFi therapy in a subset of patients with RA and axSpA beyond conception.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs wherever nitric oxide is produced in abundance.

2016 EULAR Guidelines on RA Management

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.

New EULAR Guidelines for Ultrasound Use

In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.

The Unregulated $37 Billion Supplement Industry

In 1994 there were 600 supplement companies, producing 4,000 OTC supplement products for a total revenue of about $4 billion. Today we have close to 6,000 companies, producting nearly 75,000 supplement products, bringing in $37 billion annually.  And all of this is regulated by 26 people and a budget of $5 million at the FDA.

Curbside Consults - July 2017

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases.